Cancer Screening in 2026: Who, When, and How Often?

Overview

Who needs screening, starting when, and how often? This session reviews current U.S. Preventive Services Task Force (USPSTF) recommendations for breast, cervical, colorectal, lung, and prostate cancer, including stopping rules. We cover risk stratification for patients who are not average risk, and the evidence and limits of multi-cancer early detection (MCED) blood testing. Case-based, practical, immediately usable.

Learning Objectives

• Apply current USPSTF screening recommendations for the major solid tumors, breast, cervical, colorectal, lung, and prostate—specifying the appropriate starting age, stopping age, and screening interval for average-risk patients in primary care.
• Risk-stratify patients to individualize screening decisions, identifying when family history, genetic predisposition, smoking history, breast density, or prior findings warrant earlier initiation, shorter intervals, or referral beyond standard average-risk protocols.
• Evaluate the role of emerging screening modalities, including multi-cancer early detection (MCED) blood and single organ cell free DNA testing, weighing their current evidence base, appropriate use, and limitations relative to established guideline-endorsed screening.
• Implement shared decision-making for screening choices that hinge on patient values, effectively communicating the benefits, harms, and uncertainties (overdiagnosis, false positives, life-expectancy considerations) for tests where the recommendation is conditional rather than absolute.